Exagen Inc. Common Stock (XGN)

About XGN

Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company's lead testing product is AVISE…

Sector

Health Care

Industry

Medical Specialities

Employees

216

Website

exagen.com/

Fundamentals

1-day range

$6.48$6.94

Market cap

$159.64M

P/E (trailing)

—

P/E (forward)

-15.61

EPS (trailing)

$-0.81

Dividend yield

—

Beta

2.18

Avg. volume

457.4K

Forecasts

7 analyst ratings

Exagen Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• XGN

  Exagen Inc. Common Stock

  $7.38

  ▼ 1.86%
  Market cap $159.64MP/E —
  $2.59$12.23
• YDES

  YD Bio Limited Ordinary Shares

  $4.8

  ▲ 24.03%
  Market cap $167.45MP/E —
  $1.7$25
• KEQU

  Kewaunee Scientific Corporation Common Stock

  $37.78

  ▼ 0.50%
  Market cap $108.73MP/E 10.89
  $33.27$59
• ACH

  Accendra Health Inc. Common Stock

  $1.22

  ▲ 0.83%
  Market cap $223.62MP/E —
  $0.9337$5.69
• BNR

  Burning Rock Biotech Limited American Depositary Shares

  $10.19

  ▲ 1.90%
  Market cap $93.65MP/E —
  $6.79$41.72
• SERA

  Sera Prognostics Inc. Class A Common Stock

  $2.07

  ▲ 0.49%
  Market cap $78.32MP/E —
  $1.56$3.95
• TLSI

  TriSalus Life Sciences Inc. Common Stock

  $4.85

  ▼ 1.62%
  Market cap $299.10MP/E —
  $2.2$7.95

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Exagen (XGN) Q2 2026 Earnings Call Transcript
  Yahoo · 8/11/2026
• Exagen (XGN) Stock Gets Fair Value Boost As Analysts Weigh Growth And Execution
  Yahoo · 8/6/2026
• TD Cowen Maintains Buy on Exagen, Raises Price Target to $10
  Benzinga · 8/5/2026
• Exagen Inc. 2026 Q2 - Results - Earnings Call Presentation
  SeekingAlpha · 8/5/2026
• B. Riley Securities Reiterates Buy on Exagen, Raises Price Target to $12
  Benzinga · 8/5/2026
• BTIG Maintains Buy on Exagen, Raises Price Target to $9
  Benzinga · 8/5/2026
• Exagen: The Path To Profitability Just Became More Credible
  SeekingAlpha · 8/5/2026
• Exagen Inc. Q2 2026 Earnings Call Summary
  Yahoo · 8/4/2026

• Frank Stokes · June 9, 2026 · Grant

  37.5K
• McKhann Chas · June 9, 2026 · Grant

  37.5K
• KAHN SCOTT D · June 9, 2026 · Grant

  37.5K
• ABALLI JOHN · March 12, 2026 · Grant

  100.0K @ $3.16
• ABALLI JOHN · March 12, 2026 · Grant

  150.0K
• Black Jeffrey G. · March 12, 2026 · Grant

  50.0K @ $3.16
• Black Jeffrey G. · March 12, 2026 · Grant

  75.0K @ $3.16
• ABALLI JOHN · March 3, 2026 · Grant

  2.5K @ $3.08
• ABALLI JOHN · March 3, 2026 · Sale

  15.7K @ $3.62

Institutional Ownership

March 31, 2026

Total shares held

9.57M

Total value held

$25.89M

Institutional holders

58